Long
Vaccinex LONG
Vacinex is a tiny company, $74 million market cap and approximately 29 million shares outstanding. They have beat street earnings expectations the past 2 quarters and they are working with Merck and the "keytruda" drug for an Alzheimer's "proof of concept" study. If the drug performs like it should, well, than you can guess where the price goes. 15% held by insiders, 36% held by institutions - this is critical, and only a 2% short position because everybody knows where it's going. It has a $7 price target and with any decent volume it will get to that number in a hurry. Thoughts? Comments? $NASDAQ:VCNX
Trade active
I am still long this name at a higher price. Absolutely nothing but good news here and going forward. Trades a TINY amount daily. When the street comes for it - and they will - it will be too late.Trade active
VCNX Vaccinex to Present at the Virtual Huntington’s Study Group Meeting on November 4-6, 2021 - stock is up 17% on big volume.Trade active
Symbol Date Shares Proceeds Transaction DetailsVCNX 2023-05-15 6.712M $2,512,000.00 Stock Award(Grant) at $0.37 per share.
VCNX 2023-03-31 4.146M $1,700,000.00 Stock Award(Grant) at $0.41 per share.
VCNX 2022-11-23 3.779M $2,000,000.00 Stock Award(Grant) at $0.53 per share.
VCNX 2022-01-27 3.604M $3,297,000.00 Purchase at $0.92 per share.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.